Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10483 |
Lisaftoclax
Bcl-2/Bcl-xl inhibitor 1,APG-2575 |
BCL | Apoptosis |
Lisaftoclax (Bcl-2/Bcl-xl inhibitor 1) 是一种双重 Bcl-2 和 Bcl-xl 抑制剂(IC50:2 nM 和 5.9 nM),具有抗肿瘤活性。 | |||
T6281 |
TW-37
TW 37 |
BCL | Apoptosis |
TW-37 是重组 Bcl-2、Bcl-xL 和 Mcl-1 的非肽抑制剂,Ki 值分别为 0.26、0.29和1.11μM | |||
T6748 |
A-1155463
A 1155463,A1155463,醋酸艾塞那肽 |
BCL | Apoptosis |
A-1155463是一种高效选择性的BCL-XL 抑制剂,对 BCL-XL 具有皮摩尔的结合亲和力,在Molt-4细胞中的EC50值为70 nM。 | |||
T39910 |
Desmorpholinyl Navitoclax-NH-Me
Desmorpholinyl ABT-263-NH-Me,Desmorpholinyl Navitoclax-NH-Me |
BCL | Apoptosis |
Desmorpholinyl Navitoclax-NH-Me (Desmorpholinyl ABT-263-NH-Me) is a Bcl-xL inhibitor, which can be employed alongside a CRBN ligand to synthesize XZ739, a PROTAC BCL-XL degrader [1] [2]. | |||
T6650 |
Sabutoclax
BI-97C1 |
BCL | Apoptosis |
Sabutoclax (BI-97C1) 是一种泛 Bcl-2 抑制剂,包括 Bcl-xL、Bcl-2、Mcl-1 和 Bfl-1,IC50 分别为 0.31 μM、0.32 μM、0.20 μM 和 0.62 μM。 | |||
T2101 |
Navitoclax
ABT-263 |
BCL | Apoptosis |
Navitoclax (ABT-263) 是一种 Bcl-2 抑制剂,可与 Bcl-xL、Bcl-2、Bcl-w 等蛋白结合 (Ki<1 nM),具有有效性和口服活性。Navitoclax 具有抗肿瘤活性,可以诱导细胞凋亡。 | |||
T9014 |
SKI-178
|
Apoptosis; S1P Receptor | Apoptosis; GPCR/G Protein |
SKI-178 是一种鞘氨醇激酶-1(SphK1)和 SphK2抑制剂,以 CDK1 依赖性方式诱导人急性髓性白血病细胞凋亡。 | |||
T36884 | BM-1244 | ||
BM-1244 is a potent Bcl-xL/Bcl-2 inhibitor with Kis of 134 and 450 nM for Bcl- xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC50 of 5 nM[1]. | |||
T36901 |
Pelcitoclax
|
||
Pelcitoclax (APG-1252) is a powerful inhibitor of the Bcl-2 and Bcl-xl proteins, displaying significant antineoplastic and pro-apoptotic properties[1]. | |||
T10577 | BM 957 | BCL | Apoptosis |
BM 957 is an effective Bcl-2 and Bcl-xL inhibitor (Kis: 1.2 and <1 nM; IC50s: 5.4 and 6.0 nM). | |||
T36883 | BM-1074 | ||
BM-1074 is a potent and highly efficacious inhibitor of Bcl-2/Bcl-xL with Ki value of < 1nM [1]. | |||
T79377 |
NWP-0476
|
||
NWP-0476为针对BCL-2/BCL-xL的抑制剂,其结构已优化以提高对BCL-xL的选择性。该化合物适用于复发性T-急性淋巴细胞白血病(T-ALL)的相关研究。 | |||
T40070 |
S65487 sulfate
VOB560 sulfate |
||
S65487 (VOB560) sulfate, a potent and selective Bcl-2 inhibitor, demonstrates activity against BCL-2 mutations, including G101V and D103Y. It exhibits poor affinity for MCL-1, BFL-1, and BCL-XL. Additionally, S65487 sulfate induces apoptosis and possesses anticancer activities. | |||
T36897 |
S65487
|
||
S65487 (VOB560) is a potent and selective Bcl-2 inhibitor. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 induces apoptosis and has anticaner activities[1][2]. | |||
T79171 |
Bcl-2-IN-11
|
||
Bcl-2-IN-11(compound 6)是高效选择性的Bcl-2抑制剂,具有0.9 nM的IC50。相对于Bcl-xl,其抑制作用较弱(IC50 > 1000 nM)。该化合物主要用于研究因Bcl-2家族蛋白过量表达引起的多种癌症,尤其适用于急性淋巴性白血病等恶性血液疾病。同时,Bcl-2-IN-11可以减少由Bcl-xl抑制相关的副作用,例如减少血小板。 | |||
T39135 |
S65487 hydrochloride
S65487 hydrochloride,VOB560 hydrochloride |
||
S65487 (VOB560) hydrochloride, a potent and selective Bcl-2 inhibitor, is effective against BCL-2 mutations, including G101V and D103Y. It exhibits poor affinity for MCL-1, BFL-1, and BCL-XL. This compound induces apoptosis and possesses anticancer activities. | |||
T40230 |
Mcl-1 inhibitor 6
|
||
Mcl-1 inhibitor 6 is a potent, orally active chemical compound that selectively inhibits the myeloid cell leukemia 1 (Mcl-1) protein, with a high affinity (K d = 0.23 nM) and binding activity (K i = 0.02 μM). This compound exhibits exceptional selectivity over other members of the Bcl-2 family, including Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w (K d >10 μM). Notably, Mcl-1 inhibitor 6 demonstrates strong antitumor activity. | |||
T21786 |
Apogossypolone (ApoG2)
|
||
Apogossypolone (ApoG2) 是一种具有口服活性的Bcl-2 家族蛋白抑制剂,对 Bcl-2, Mcl-1 和 Bcl-XL 的Ki 值分别为 35, 25 和 660 nM。Apogossypolone 具有抗肿瘤活性,可诱导细胞凋亡 (apoptosis) 和 自噬 (autophagy)。Apogossypolone 具有抗真菌活性。 |